Worker Protection from Heat Stress: Now More Than Ever, It's Up to Employers to Do The Right Thing

St. Paul, MN, June 13, 2025 (GLOBE NEWSWIRE) — With federal cost-cutting and deregulation reshaping workplace safety oversight, the responsibility to protect workers from extreme heat is falling squarely on employers. While OSHA's National Emphasis Program (NEP) on Heat Stress has been extended for another year, the long-anticipated federal heat stress standard is looking less likely than ever. That means worksites will need to rely on existing guidance, industry best practices, and—more than anything—their own commitment to doing what's right.
'The reality is, a federally mandated heat stress standard in the U.S. may not happen anytime soon,' says Greg Schrab, President at Ergodyne, a leader in safety work gear and heat stress prevention. 'But regulation should never be the reason we protect workers. Employers don't need a federal rule to tell them that heat stress is dangerous, or that simple, proven solutions can save lives.'
With extreme heat becoming a predictable threat year after year, safety professionals are stepping up where federal regulations fall short—turning to resources like OSHA's NEP, ANSI/ASSP A10.50-2024, state regulations, and industry safety leaders to build and reinforce heat stress prevention programs that work.
From implementing hydration and rest schedules to providing personal cooling gear, the industry's best practices are well-documented. The challenge for many employers isn't knowing what to do—it's making sure it gets done.
Randy Milliron, Safety Manager for the City of Gillette, Wyoming, agrees. He points to time-tested basics as the foundation of his program. 'It will sound so rudimentary, but if you keep to the classics you can safely work outside when the thermostat starts to rise. Drinking plenty of fluids, monitoring urine output and color, taking breaks in the shade, and looking out for your co-workers are the key things to help you stay cool and hydrated.'
To help worksites put prevention into practice, Ergodyne is expanding its cooling gear and heat stress solutions with new advancements in wearable cooling, flame-resistant cooling PPE, and turnkey heat stress prevention kits. But gear is only part of the equation. The St. Paul, MN-based worksite safety leader and cooling category pioneer is in the field working alongside employers to provide on-site education in support of company heat stress prevention programs.
'Unless you are attending safety conferences and rubbing elbows with the vendors who provide this type of PPE, you might not know of all the advancements that have been made in these product lines,' Milliron says. 'So, I believe it is necessary, if you are a safety professional, to find those subject-matter experts who specialize in cooling products and create long-lasting friendships with them.'
Milliron has seen firsthand how proactive prevention can make a difference. 'Last summer we had a seasonal employee try to work through the early signs and symptoms of heat illness. By the time I arrived, he was in bad shape. We moved him into the air-conditioned office and applied ice packs and a cooling towel to his groin and neck. It took a very long time for his symptoms to subside, but the cooling towel did the trick at lowering his core body temperature.'
By leveraging proven cooling solutions and industry-backed guidance, safety leaders can make sure their teams stay safe, stay productive, and stay protected—regardless of what happens at the federal level.
'In the absence of federal action, it's up to employers to step up,' says Lexi Engelbart, Product Manager at Ergodyne and Vice Chair of the International Safety Equipment Association's (ISEA) Heat Stress Solutions Group. 'Not because they have to, but because it's the right thing to do.'
For more heat stress education, including signs, symptoms, and solutions, visit ergodyne.com/heat-stress.
ABOUT ERGODYNE
Since 1983, Tenacious Holdings, Inc. (dba Ergodyne, a Klein Tools Company) has pioneered the development of products that Make The Workplace A Betterplace™. What started with just one product has grown into a line of top flight, battle-tested, Tenacious Work Gear®; all precision crafted to provide protection, promote prevention and manage the elements for workers on jobsites the world over. The current lineup is extensive and constantly growing: ProFlex® Hand Protection, ProFlex® Knee Pads, ProFlex® Supports, Skullerz® Head & Face Protection, Skullerz® Eye Protection, Trex® Traction, KREW'D® Skin Protection, Chill-Its® Cooling Products, N-Ferno® Warming Products, GloWear® Hi-Vis Apparel, Squids® Lanyards, Arsenal® Gear and Tool Storage, and SHAX® Portable Work Shelters.
Originally posted on: www.ergodyne.com
Attachment New Heat Stress Hazard Solutions
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

2 hours ago

Crash dummies used in car safety tests are still modeled after men despite higher risks for women

Maria Weston Kuhn had one lingering question about the car crash that forced her to have emergency surgery during a vacation in Ireland: Why did she and her mother sustain serious injuries while her father and brother, who sat in the front, emerge unscathed? 'It was a head-on crash and they were closest to the point of contact," said Kuhn, now 25, who missed a semester of college to recover from the 2019 collision that caused her seat belt to slide off her hips and rupture her intestines by pinning them against her spine. "That was an early clue that something else was going on.' When Kuhn returned home to Maine, she found an article her grandma had clipped from Consumer Reports and left on her bed. Women are 73% more likely to be injured in a frontal crash, she learned, yet the dummy used in vehicle tests by the National Highway Traffic Safety Administration dates back to the 1970s and is still modeled almost entirely off the body of a man. Kuhn, who is starting law school at New York University this fall, took action and founded the nonprofit Drive US Forward. Its aim was to raise public awareness and eventually encourage members of Congress to sign onto a bill that would require NHTSA to incorporate a more advanced female dummy into its testing. The agency has the final word on whether cars get pulled from the market, and the kind of dummy used in its safety tests could impact which ones receive coveted five-star ratings. 'It seems like we have an easy solution here where we can have crash test dummies that reflect an average woman as well as a man,' Sen. Deb Fischer, a Nebraska Republican who has introduced the legislation the past two sessions, told The Associated Press. Senators from both parties have signed onto Fischer's 'She Drives Act,' and the transportation secretaries from the past two presidential administrations have expressed support for updating the rules. But for various reasons, the push for new safety requirements has been moving at a sluggish pace. That's particularly true in the U.S., where much of the research is happening and where around 40,000 people are killed each year in car crashes. The crash test dummy currently used in NHTSA five-star testing is called the Hybrid III, which was developed in 1978 and modeled after a 5-foot-9, 171-pound man (the average size in the 1970s but about 29 pounds lighter than today's average). What's known as the female dummy is essentially a much smaller version of the male model with a rubber jacket to represent breasts. It's routinely tested in the passenger seat or the back seat but seldom in the driver's seat, even though the majority of licensed drivers are women. 'What they didn't do is design a crash test dummy that has all the sensors in the areas where a woman would be injured differently than a man,' said Christopher O'Connor, president and CEO of the Farmington Hills, Michigan-based Humanetics Group, which has spent more than a decade developing and refining one. A female dummy from Humanetics equipped with all of the available sensors costs around $1 million, about twice the cost of the Hybrid used now. But, O'Connor says, the more expensive dummy far more accurately reflects the anatomical differences between the sexes — including in the shape of the neck, collarbone, pelvis, and legs, which one NHTSA study found account for about 80% more injuries by women in a car crash compared to men. Such physical dummies will always be needed for vehicle safety tests, and to verify the accuracy of virtual tests, O'Connor said. Europe incorporated the more advanced male dummy developed by Humanetics' engineers, the THOR 50M (based on a 50th percentile man), into its testing procedures soon after Kuhn's 2019 crash in Ireland. Several other countries, including China and Japan, have adopted it as well. But that model and the female version the company uses for comparison, the THOR 5F (based on a 5th percentile woman), have been met with skepticism from some American automakers who argue the more sophisticated devices may exaggerate injury risks and undercut the value of some safety features such as seat belts and airbags. Bridget Walchesky, 19, had to be flown to a hospital, where she required eight surgeries over a month, after a 2022 crash near her home in Sheboygan, Wisconsin, that killed her friend, who was driving. While acknowledging the seat belt likely saved her life, Walchesky said some of the injuries — including her broken collarbone — were the result of it pinning her too tightly, which she views as something better safety testing focused on women could improve. 'Seat belts aren't really built for bodies on females,' Walchesky said. 'Some of my injuries, the way the force hit me, they were probably worsened.' The Alliance for Automotive Innovation, an industry trade group, said in a statement to the AP that the better way to ensure safety — which it called its top priority — is through upgrades to the existing Hybrid dummy rather than mandating a new one. 'This can happen on a faster timeline and lead to quicker safety improvements than requiring NHTSA to adopt unproven crash test dummy technology,' the alliance said. Humanetics' THOR dummies received high marks in the vehicle safety agency's early tests. Using cadavers from actual crashes to compare the results, NHTSA found they outperformed the existing Hybrid in predicting almost all injuries — including to the head, neck, shoulders, abdomen and legs. A separate review by the Insurance Institute for Highway Safety, a research arm funded by auto insurers, was far more critical of the dummy's ability to predict chest injuries in a frontal crash. Despite the vast expansion in the number of sensors, the insurance institute's testing found, the male THOR dummy was less accurate than the current Hybrid dummies, which also had limitations. 'More isn't necessarily better,' said Jessica Jermakian, senior vice president for vehicle research at IIHS. 'You also have to be confident that the data is telling you the right things about how a real person would fare in that crash." NHTSA's budget plan commits to developing the female THOR 5F version with the ultimate goal of incorporating it into the testing. But there could be a long wait considering the THOR's male version adopted by other countries is still awaiting final approval in the U.S. A 2023 report by the Government Accountability Office, which conducts research for Congress, cited numerous 'missed milestones' in NHTSA's development of various crash dummy enhancements — including in the THOR models. Kuhn acknowledges being frustrated by the slow process of trying to change the regulations. She says she understands why there's reluctance from auto companies if they fear being forced to make widespread design changes with more consideration for women's safety. 'Fortunately, they have very skilled engineers and they'll figure it out,' she said.

Yahoo

8 hours ago

• Yahoo

Mom of 8 with Stage 3 Breast Cancer Breaks Down in Tears After Unexpected Call From School Nurse (Exclusive)

Misty De La Cruz is a mother of eight who is battling an aggressive form of breast cancer Since her diagnosis in 2024, the 43-year-old has been open about her health struggles with her family, and especially with her children De La Cruz was heartbroken after she received an unexpected call from the elementary school nurse regarding her younger sonMisty De La Cruz was diagnosed with stage 3 triple-negative breast cancer in September 2024 after discovering a lump during one of her monthly self-exams. In May 2025, the Maryland-based mother of eight received an unexpected call from her son's elementary school. Over the phone, a nurse explained that the 10-year-old was frequently exhausted during school hours, telling the staff he's afraid to fall asleep most nights in fear that his mom might pass away overnight. De La Cruz filmed her emotional reaction to the heartbreaking phone call on TikTok, amassing over 3 million views. De La Cruz, who is battling the side effects of treatment while trying to maintain a stable family, says the emotional toll cancer takes extends far beyond the physical. For her, it's not just about surviving, it's about holding together a household deeply affected by fear and uncertainty. 'As a parent you try to be strong for your children, but they watch you slowly change into someone completely different,' De La Cruz tells PEOPLE exclusively. After her diagnosis, the 43-year-old sat down with her older children and was honest about what she was facing. It took a bit more time to have that conversation with her younger son. When she finally did, De La Cruz spoke with him one-on-one, gently explaining what cancer is and how it would impact both her health and their daily lives. 'He was crying, and the only thing he asked was if I was going to die,' she recalls. 'I tried to reassure him that the doctors were going to do the best that they could do to make sure that that didn't happen. But ultimately, there is never a promise from anyone, but I was gonna fight as hard as I could.' As months pass by, De La Cruz can no longer manage simple tasks she once took for granted. For example, standing in the kitchen to cook meals for her family is now a struggle. Chemotherapy has taken a serious toll on her body, and she often has negative reactions to the treatment and feels the side effects almost immediately. 'You lose all sense of humility or embarrassment because there are days when you can't even wash yourself and need assistance,' she explains. 'The debilitating pain from the neuropathy makes it impossible to even stand up at times. The bone and muscle pain from the injections made me need to use a walker at 42 years old because I couldn't even stand up on my own.' Working to cover basic expenses is also difficult, but even more heartbreaking is not being able to take care of her younger children when they're sick. She also has to miss her kids' activities because her weak immune system makes even a minor illness potentially life-threatening. 'You just feel helpless and useless and a burden all at the same time,' she candidly tells PEOPLE. While her children's schools were informed early on about her illness and have offered unwavering support, receiving a call from the elementary school nurse left her in tears. "It's one of those calls no parent wants to receive,' De La Cruz says. 'The feeling is gut-wrenching. It's almost like someone knocked the wind out of you, and you really don't know how to react to it. All I could do was cry.' When her son got home from school, she made sure they talked and decided that therapy was the best route for him. 'I allow my son to ask all of the questions he wants to ask, and I answer them honestly. I don't believe in tiptoeing around something or masking what the situation really is,' she reveals. 'We've had open discussions about my chances of survival as well as how it's going to change our lives on a daily basis.' Yet, no matter how sensitively she approaches the topic, De La Cruz still senses that her children worry about losing her. 'It doesn't take away the fear and a child's eyes as they watch the person who's always been the strongest in the household become the weakest,' she admits. De La Cruz has told each of her children that if they ever felt the need to talk to a professional, she would gladly arrange it. When it comes to creating small moments of normalcy around the house, De La Cruz says sticking to a routine helps a lot. 'No matter how sick I am, every Sunday our family has a Sunday dinner,' she reveals. 'Usually, I'm the one to do all the cooking, but we've had to improvise.' She's had to rely on her children more than ever, especially in the kitchen, as she can no longer stand for more than a few minutes at a time. Nevertheless, cooking together brings them joy. What she's learned through cancer is this: be honest with your children. Let them feel what they feel— anger, sadness, confusion. 'Everyone grieves differently,' she says, 'and this is a grieving process. You won't be the person you were before cancer.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories. One of the hardest but most important lessons was learning to accept help. As someone deeply independent, leaning on others felt unnatural at first. But she came to understand that "it doesn't mean you're weak… It just means you're human – and even the strongest humans need help.' She wants others to know that the financial toll is real and often hidden. 'A lot of people fail to understand that just because you physically survive cancer, it doesn't mean that you emotionally mentally or financially survive it,' she emphasizes. 'I had to create a GoFundMe to attempt to not lose our home due to the unbelievable cost of trying to survive.' Her advice to others facing this journey is to speak openly, accept support, and don't be ashamed to ask for help. Survival isn't just about your body – it's about your whole life. And healing takes time. Read the original article on People

Business Upturn

11 hours ago

• Business Upturn

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

By GlobeNewswire Published on June 23, 2025, 00:35 IST New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety concerns in adults and adolescents with haemophilia A, with or without inhibitors 1 . . Switching to Mim8 led to a sustained increase in thrombin generation into the normal range, but without causing thrombin levels that might pose a thrombotic risk 1 . . FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with strong user preference over their emicizumab injection system 2 . . These results add to the overall safety profile of Mim8 based on the FRONTIER clinical trial programme3. Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C. In the study, the first Mim8 maintenance dose was administered on the next planned emicizumab dosing day. Patients were given the option of switching to once-monthly, once every two weeks or once-weekly dosing frequencies of Mim8, regardless of their prior dosing frequency1,3. Steady-state Mim8 concentration was achieved by Week 16, and emicizumab elimination was completed by Week 261. Switching to Mim8 led to a sustained increase in thrombin peak levels without an exaggerated thrombin response1. 'Continuous prophylactic coverage is critical to avoiding breakthrough bleeds in people living with haemophilia; with new non-factor therapeutic options, many people could have hesitations about switching treatment options. These data demonstrate that switching to Mim8 from emicizumab can be done without requiring a washout period,' said Allison P. Wheeler, MD, Washington Center for Bleeding Disorders, Seattle, WA. 'This is critical in ensuring that individuals maintain continuous protection against bleeding events as we seek to help address the ongoing needs of people living with this complex disease.' The open-label phase 3b FRONTIER5 study consisted of 61 adults and adolescents, aged 12 years and older, with haemophilia A. Mim8 was well-tolerated with no safety concerns. No thromboembolic events, hypersensitivity reactions, or treatment-emergent adverse events (TEAEs) leading to discontinuation were observed, and there was no clinical evidence of neutralising anti-Mim8 antibodies1. The PROs data from FRONTIER5 indicated a strong overall preference for the Mim8 pen-injector, with 97% (n=57/59) of patients reporting a 'very strong' or 'fairly strong' preference in comparison to their previous emicizumab injection system2. Of the participants who completed the Haemophilia Device Handling and Preference Assessment (HDHPA) questionnaire at week 26, 98% (n=58/59) found the Mim8 pen-injector 'very easy' or 'easy' to use, and 95% (n=56/59) found it 'much easier' or 'easier' compared with their previous administration method. All participants (100%) were 'extremely confident' or 'very confident' in using the pen-injector correctly, and most participants (83%; n=49/59) found it 'very easy' to inject the dose2. 'The FRONTIER5 safety and patient-reported outcomes data support Mim8 as a potential future treatment option for people living with haemophilia A and demonstrate our continued commitment to developing innovative treatment options for this community', said Stephanie Seremetis, chief medical officer and CVP for Haemophilia at Novo Nordisk. 'These results give valuable insights into haemophilia A management, highlight the feasibility of directly switching to Mim8 from emicizumab, and reveal a strong patient preference for the Mim8 pen-injector device.' Novo Nordisk expects to submit Mim8 for regulatory review during 2025. Data from the ongoing phase 3 FRONTIER programme will be disclosed at upcoming congresses and in publications in 2025 and 2026. About haemophilia Haemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding4. It is estimated to affect approximately 1,125,000 people worldwide5. There are different types of haemophilia, which are characterised by the type of clotting factor protein that is defective or missing4. Haemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and haemophilia B is caused by a missing or defective clotting Factor IX4. Inhibitors are an immune system response to the clotting factors in replacement therapy. Currently, it is estimated that up to 30% of people living with severe haemophilia A develop inhibitors6 that can cause replacement therapies to stop working. About Mim8 Mim8 is an investigational FVIIIa mimetic bispecific antibody optimised with the aim to deliver improved potency and sustained efficacy across flexible dosing intervals up to once-monthly prophylaxis for people living with haemophilia A, with or without inhibitors7-10. Administered under the skin, Mim8 bridges Factor IXa and Factor X. This action replaces FVIII function, which helps restore the body's thrombin generation capacity into the normal range, helping blood to clot7,11. The use of Mim8 in people living with haemophilia A is investigational and not approved by regulatory authorities or available anywhere in the world. About the FRONTIER5 trial FRONTIER5 is a single-arm, open-label, 26-week, phase 3b trial evaluating the safety of switching from previous emicizumab prophylaxis treatment directly to Mim8 prophylaxis treatment using the Mim8 pen-injector in adults and adolescents with haemophilia A, with or without inhibitors3. The FRONTIER clinical programme investigates Mim8 as a prophylaxis treatment for people with haemophilia A, with or without inhibitors. This programme includes FRONTIER1, FRONTIER2, FRONTIER3, FRONTIER4 and FRONTIER53,12-15. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information _______________________ References Oldenberg J, Benson G, Chowdaryet P, et al. FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21-25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13686. Mahlangu J, Ahuja S, Cockrell E, et al. FRONTIER5 device handling and patient-reported outcomes. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21–25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13786. A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER5). Available at: Last accessed: June 2025. MedlinePlus. Hemophilia. Available at: Last accessed: June 2025. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171:540–546. doi: 10.7326/M19-1208. Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019;54:204-209. doi: 10.5045/br.2019.54.3.204. Ostergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138:1258-1268. doi: 10.1182/blood.2020010331. Mancuso EM, et al. Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: Phase 3, open-label, randomized, controlled FRONTIER2 study. Abstract presented at the International Society on Thrombosis and Haemostasis (ISTH) 2024 Congress. Kenet G, et al. Patient- and caregiver-reported outcomes with subcutaneous Mim8 prophylaxis in paediatric patients with haemophilia A with or without factor VIII inhibitors: phase 3 FRONTIER3 study. Abstract presented at the European Association for Haemophilia and Allied Disorders (EAHAD) 2025 Annual Congress. Session 6. Chowdary P, Banchev AM, Kavakli K, et al. Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study. Abstract presented at the American Society of Hematology (ASH) 2024 Annual Congress. Session: 322. U.S. National Library of Medicine. F8 gene. MedlinePlus Genetics. Available at Last accessed: June 2025. A Research Study Investigating Mim8 in People With Haemophilia A (FRONTIER1). Available at: Last accessed: June 2025. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors. Available at: Last accessed: June 2025. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors. Available at: Last accessed: June 2025. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER4). Available at: Last accessed: June 2025. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.